Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Isolated Limb Infusion with Melphalan and Dactinomycin for Melanoma and Sarcoma
NCT00004250Phase 2Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Aug 1999
- Primary completion
- Jun 2007
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of melphalan and actinomycin D in melanoma and soft tissue sarcoma (STS), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoints: Efficacy of isolated limb infusion at 8 weeks, Morbidity of patients and 1 more. Started Aug 1999; status: completed.
02
Drugs
melphalanactinomycin D
03
Conditions
melanomasoft tissue sarcoma (STS)
Beyond the preview
Go deeper on NCT00004250.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00004250.